PhD – Interim CEO
Dr. Goddard is actively involved in the Biotechnology industry as a board director and
executive. He works as an investor and board member in a number of early stage and
public biotechnology companies, leveraging over 30 years of experience in the industry.
From October 1998, until it’s $4 billion acquisition by Astellas Pharmaceuticals, Inc. in
June of 2010, Dr. Goddard was CEO of OSI Pharmaceuticals, Inc. a company he joined as
a scientist in 1989. In this role he raised over $1.5 billion and oversaw the development,
approval and commercial launch of Tarceva®, a leading lung cancer medicine.
He is Chairman of the board of Mission Therapeutics, and a board member at Hibercell, Inc., Ryvu Therapeutics and BlinkBio, Inc. He has been active in many organizations that support cancer research and awareness, science education and the biotechnology industry. He received his PhD in Cancer Pharmacology in the UK in 1985 and conducted his post-doctoral research at the National Cancer Institute in Bethesda, MD.
PhD – Head of Chemistry
Ulrich Lücking, PhD, is a drug discovery leader with 20 years of industrial experience in small molecule research. As a project leader and inventor at Bayer AG and Schering AG his efforts were instrumental in the identification of six clinical candidates so far, including the highly potent and selective ATR inhibitor BAY 1895344. During all his path Ulrich has contributed to the exploration of novel chemical space, for instance with his innovative applications of sulfoximines or macrocycles in drug discovery.
Prior to joining industry, Ulrich studied chemistry at the University of Hannover and at the University of Cambridge. He completed his PhD at the Max Planck Institute for Coal Research in Müllheim an der Ruhr, and then carried out his post-doctoral training at the Scripps Research Institute in La Jolla.
Sotirios K. Sotiriou
PhD – Head of Biology
Sotirios Sotiriou, PhD, is a Molecular Cancer Biologist currently working as the Head of Biology at FoRx Therapeutics. Previously, he worked as a postdoctoral fellow at Dana-Farber Cancer Institute/Harvard Medical School, Broad Institute of MIT and Harvard and University of Geneva. Sotirios received his PhD degree with great distinction in Molecular Biology from the University of Geneva.
Sotirios completed his undergraduate studies in Biological Applications and Technology at the University of Ioannina. His research interests focus on DNA repair, DNA replication, and the mechanisms underlying genomic instability in human cancers.